Cargando…
Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark
Background: Patients with systemic lupus erythematosus (SLE) have an increased risk of infections due to impaired immune functions, disease activity, and treatment. This study investigated the impact of having SLE on the incidence of hospitalisation with COVID-19 infection. Methods: This was a natio...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432052/ https://www.ncbi.nlm.nih.gov/pubmed/34501290 http://dx.doi.org/10.3390/jcm10173842 |
_version_ | 1783751074177351680 |
---|---|
author | Cordtz, René Kristensen, Salome Dalgaard, Louise Plank Holm Westermann, Rasmus Duch, Kirsten Lindhardsen, Jesper Torp-Pedersen, Christian Dreyer, Lene |
author_facet | Cordtz, René Kristensen, Salome Dalgaard, Louise Plank Holm Westermann, Rasmus Duch, Kirsten Lindhardsen, Jesper Torp-Pedersen, Christian Dreyer, Lene |
author_sort | Cordtz, René |
collection | PubMed |
description | Background: Patients with systemic lupus erythematosus (SLE) have an increased risk of infections due to impaired immune functions, disease activity, and treatment. This study investigated the impact of having SLE on the incidence of hospitalisation with COVID-19 infection. Methods: This was a nationwide cohort study from Denmark between 1 March 2020 to 2 February 2021, based on the linkage of several nationwide registers. The adjusted incidence of COVID-19 hospitalisation was estimated for patients with SLE compared with the general population in Cox-regression models. Among SLE patients, the hazard ratio (HR) for hospitalisation was analysed as nested case-control study. Results: Sixteen of the 2533 SLE patients were hospitalised with COVID-19 infection. The age-sex adjusted rate per 1000 person years was 6.16 (95% CI 3.76–10.08) in SLE patients, and the corresponding hazard ratio was 2.54 (95% CI 1.55–4.16) compared with the matched general population group after adjustment for comorbidities. Among SLE patients, hydroxychloroquine treatment was associated with a HR for hospitalisation of 0.61 (95% CI 0.19–1.88), and 1.06 (95% CI 0.3–3.72) for glucocorticoid treatment. Conclusion: Patients with SLE were at increased risk of hospitalisation with COVID-19. |
format | Online Article Text |
id | pubmed-8432052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84320522021-09-11 Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark Cordtz, René Kristensen, Salome Dalgaard, Louise Plank Holm Westermann, Rasmus Duch, Kirsten Lindhardsen, Jesper Torp-Pedersen, Christian Dreyer, Lene J Clin Med Article Background: Patients with systemic lupus erythematosus (SLE) have an increased risk of infections due to impaired immune functions, disease activity, and treatment. This study investigated the impact of having SLE on the incidence of hospitalisation with COVID-19 infection. Methods: This was a nationwide cohort study from Denmark between 1 March 2020 to 2 February 2021, based on the linkage of several nationwide registers. The adjusted incidence of COVID-19 hospitalisation was estimated for patients with SLE compared with the general population in Cox-regression models. Among SLE patients, the hazard ratio (HR) for hospitalisation was analysed as nested case-control study. Results: Sixteen of the 2533 SLE patients were hospitalised with COVID-19 infection. The age-sex adjusted rate per 1000 person years was 6.16 (95% CI 3.76–10.08) in SLE patients, and the corresponding hazard ratio was 2.54 (95% CI 1.55–4.16) compared with the matched general population group after adjustment for comorbidities. Among SLE patients, hydroxychloroquine treatment was associated with a HR for hospitalisation of 0.61 (95% CI 0.19–1.88), and 1.06 (95% CI 0.3–3.72) for glucocorticoid treatment. Conclusion: Patients with SLE were at increased risk of hospitalisation with COVID-19. MDPI 2021-08-27 /pmc/articles/PMC8432052/ /pubmed/34501290 http://dx.doi.org/10.3390/jcm10173842 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cordtz, René Kristensen, Salome Dalgaard, Louise Plank Holm Westermann, Rasmus Duch, Kirsten Lindhardsen, Jesper Torp-Pedersen, Christian Dreyer, Lene Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark |
title | Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark |
title_full | Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark |
title_fullStr | Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark |
title_full_unstemmed | Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark |
title_short | Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark |
title_sort | incidence of covid-19 hospitalisation in patients with systemic lupus erythematosus: a nationwide cohort study from denmark |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432052/ https://www.ncbi.nlm.nih.gov/pubmed/34501290 http://dx.doi.org/10.3390/jcm10173842 |
work_keys_str_mv | AT cordtzrene incidenceofcovid19hospitalisationinpatientswithsystemiclupuserythematosusanationwidecohortstudyfromdenmark AT kristensensalome incidenceofcovid19hospitalisationinpatientswithsystemiclupuserythematosusanationwidecohortstudyfromdenmark AT dalgaardlouiseplankholm incidenceofcovid19hospitalisationinpatientswithsystemiclupuserythematosusanationwidecohortstudyfromdenmark AT westermannrasmus incidenceofcovid19hospitalisationinpatientswithsystemiclupuserythematosusanationwidecohortstudyfromdenmark AT duchkirsten incidenceofcovid19hospitalisationinpatientswithsystemiclupuserythematosusanationwidecohortstudyfromdenmark AT lindhardsenjesper incidenceofcovid19hospitalisationinpatientswithsystemiclupuserythematosusanationwidecohortstudyfromdenmark AT torppedersenchristian incidenceofcovid19hospitalisationinpatientswithsystemiclupuserythematosusanationwidecohortstudyfromdenmark AT dreyerlene incidenceofcovid19hospitalisationinpatientswithsystemiclupuserythematosusanationwidecohortstudyfromdenmark |